JP2009543876A5 - - Google Patents

Download PDF

Info

Publication number
JP2009543876A5
JP2009543876A5 JP2009520867A JP2009520867A JP2009543876A5 JP 2009543876 A5 JP2009543876 A5 JP 2009543876A5 JP 2009520867 A JP2009520867 A JP 2009520867A JP 2009520867 A JP2009520867 A JP 2009520867A JP 2009543876 A5 JP2009543876 A5 JP 2009543876A5
Authority
JP
Japan
Prior art keywords
annexin
therapeutic composition
binding agent
modified
iri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009520867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009543876A (ja
Filing date
Publication date
Priority claimed from US11/486,667 external-priority patent/US7645739B2/en
Application filed filed Critical
Publication of JP2009543876A publication Critical patent/JP2009543876A/ja
Publication of JP2009543876A5 publication Critical patent/JP2009543876A5/ja
Pending legal-status Critical Current

Links

JP2009520867A 2006-07-14 2007-04-12 再灌流障害の減弱 Pending JP2009543876A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/486,667 US7645739B2 (en) 2001-02-21 2006-07-14 Modified annexin compositions and methods of using same
PCT/US2007/066561 WO2008008561A2 (en) 2006-07-14 2007-04-12 Attenuation of reperfusion injury

Publications (2)

Publication Number Publication Date
JP2009543876A JP2009543876A (ja) 2009-12-10
JP2009543876A5 true JP2009543876A5 (OSRAM) 2011-05-12

Family

ID=38923973

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520867A Pending JP2009543876A (ja) 2006-07-14 2007-04-12 再灌流障害の減弱

Country Status (6)

Country Link
US (1) US7645739B2 (OSRAM)
EP (2) EP2040729A4 (OSRAM)
JP (1) JP2009543876A (OSRAM)
AU (1) AU2007272804A1 (OSRAM)
CA (1) CA2658431A1 (OSRAM)
WO (2) WO2008008561A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050222030A1 (en) * 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US20090291086A1 (en) * 2001-02-21 2009-11-26 Alavita Pharmaceuticals, Inc. Compositions and Methods for Treating Cerebral Thrombosis and Global Cerebral Ischemia
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
JP5463616B2 (ja) * 2007-11-29 2014-04-09 大日本印刷株式会社 有機ｅｌ素子、有機ｅｌディスプレイ及びカラーフィルター
SI2234631T1 (sl) * 2007-12-18 2013-02-28 Athera Biotechnologies Ab Spojine in postopki za zdravljenje ĺ˝ilne bolezni
ES2733902T3 (es) 2008-02-22 2019-12-03 Annexin Pharmaceuticals Ab Compuestos y procedimientos para la prevención o tratamiento de reestenosis
EP2349321B1 (en) * 2008-10-17 2020-04-22 London Health Sciences Centre Research Inc. Annexin and its use to treat inflammatory disorders
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
WO2015025956A1 (ja) * 2013-08-22 2015-02-26 国立大学法人九州大学 心筋障害治療用薬剤組成物、心筋障害予防用薬剤組成物、心不全治療用薬剤組成物、心不全予防用薬剤組成物、心筋障害又は心不全を治療又は予防する方法、ｍｆｇ－ｅ８、ｍｆｇ－ｅ８の使用、及び心筋障害又は心不全を治療又は予防する化合物のスクリーニング方法
GB2542391A (en) 2015-09-17 2017-03-22 Annexin Pharmaceuticals Ab Process of manufacture
WO2018136455A1 (en) * 2017-01-17 2018-07-26 The Texas A&M University System Endolysosomal targeting conjugates for improved delivery of cargo molecules to the endolysosomal compartment of target cells
CN111494608A (zh) * 2020-05-08 2020-08-07 北京大学第三医院（北京大学第三临床医学院） 预防或治疗子痫前期及相关病症的药物及其应用

Family Cites Families (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
DE3315000A1 (de) * 1983-04-26 1984-10-31 Behringwerke Ag, 3550 Marburg Gewebeprotein pp(pfeil abwaerts)4(pfeil abwaerts), verfahren zu seiner gewinnung sowie seine verwendung
US5066788A (en) * 1984-09-21 1991-11-19 Boehringer Ingelheim International Gmbh Blood coagulation inhibiting proteins, processes for preparing them and their uses
KR930007434B1 (ko) * 1984-09-21 1993-08-10 베링거 잉겔하임 인터내셔날 게엠베하 혈액응고 억제 단백질 제조방법
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
CA1265446A (en) * 1985-09-30 1990-02-06 Masahiro Maki Anticoagulating substance, process for preparing same and anticoagulant comprising same as an effective component
JPH08840B2 (ja) * 1986-11-14 1996-01-10 興和株式会社 抗ｐｃｉモノクローナル抗体、これを用いた抗ｐｃｉの精製法及び免疫学的測定法
DE3643182A1 (de) * 1986-12-18 1988-06-30 Behringwerke Ag Arzneimittel enthaltend das gewebeprotein pp4, verfahren zur herstellung von pp4 und zu seiner pasteurisierung sowie die verwendung von pp4
US4937324A (en) * 1987-02-06 1990-06-26 Zymogenetics, Inc. Chromatographic purification of human proteins having anticoagulant and anti-inflammatory activity
JP2660514B2 (ja) * 1987-02-20 1997-10-08 興和株式会社 抗血液凝固作用を有するポリペプチド
PT87083B (pt) * 1987-03-28 1992-07-31 Boehringer Ingelheim Int Processo para a preparacao de uma proteina anticoagulante vascular, de adn que codifica para esta proteina e de composicoes farmaceuticas que a contem
US4965251A (en) * 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
DE3737239A1 (de) 1987-11-03 1989-10-12 Behringwerke Ag Gentechnische herstellung von anticoagulatorischem protein pp4
ATE124087T1 (de) * 1988-02-26 1995-07-15 Biogen Inc Dna-sequenzen, rekombinante dna-moleküle und verfahren zur herstellung von lipocortin iii, iv, v, und vi.
US5324844A (en) * 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0409053B1 (de) * 1989-07-15 1993-09-29 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Reinigung von Annexinen
EP0409052B1 (de) * 1989-07-15 1993-05-12 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Antikoagulanz enthaltendes Mittel
DE3937607A1 (de) 1989-11-11 1991-05-16 Boehringer Ingelheim Int Verwendung eines antikoagulanz zur behandlung von tumorerkrankungen
DE3942081A1 (de) * 1989-12-20 1991-06-27 Behringwerke Ag Mittel zur verbesserung der wiederfindung von annexinen
US5627036A (en) * 1989-12-27 1997-05-06 Boehringer Ingelheim International Gmbh Use of an anticoagulant as a diagnostic agent
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
CA2081474A1 (en) 1990-05-08 1991-11-09 Manzer Durrani Direct spray-dried drug/lipid powder composition
JPH06502407A (ja) 1990-11-02 1994-03-17 ジェネンテク，インコーポレイテッド 血小板凝集阻害剤
US5360789A (en) * 1990-11-20 1994-11-01 Kowa Co., Ltd. Therapeutic agent for skin or corneal disease
JP2916947B2 (ja) 1990-11-28 1999-07-05 興和株式会社 Ｃｐｂ―ｉの安定化方法及び製剤組成物
US5229367A (en) * 1991-01-21 1993-07-20 Sclavo S.P.A. Antiinflammatory peptide derived from human lipocortin V
EP0538459A4 (en) 1991-05-09 1993-06-16 The Board Of Regents Of The University Of Washington Phospholipid-targeted thrombolytic agents
US5632986A (en) * 1991-05-09 1997-05-27 The University Of Washington Phospholipid-targeted thrombolytic agents
JPH051096A (ja) 1991-06-26 1993-01-08 Kowa Co 抗血液凝固活性を持つオリゴペプチド
EP0646019B9 (en) * 1992-06-09 2002-12-18 Neorx Corporation Biotin-DOTA conjugates and their use in pretargeting methods
AU676483B2 (en) 1992-07-08 1997-03-13 N.V. Innogenetics S.A. Polypeptides, derived from endonexin 2, having hepatitis B virus receptor activity and their use in diagnostic and pharmaceutical compositions
JP3416912B2 (ja) 1992-10-08 2003-06-16 興和株式会社 抗血液凝固活性を持つオリゴペプチド
JPH0772149A (ja) 1993-06-30 1995-03-17 Nippon Shinyaku Co Ltd 肝癌又は肝硬変の診断薬及び診断法
JPH0772147A (ja) 1993-07-02 1995-03-17 Noboru Kaneko 抗アネキシンｖ抗体並びに該抗体の製法及び利用
US5849600A (en) * 1993-11-10 1998-12-15 The Mclean Hospital Corporation Diagnostic assays for Alzheimer's disease
US5968477A (en) 1994-01-24 1999-10-19 Neorx Corporation Radiolabeled annexin conjugates with hexose and a chelator
WO1995034315A1 (en) 1994-06-16 1995-12-21 Neorx Corporation Radiolabeled annexin-galactose conjugates
WO1996003655A1 (en) 1994-07-23 1996-02-08 Boehringer Mannheim Gmbh Method for the determination of the prethrombotic state
DE19541284C2 (de) 1995-11-06 1998-09-24 Kalden Joachim Robert Prof Dr Verfahren zur Immunmodulation
RU2178307C2 (ru) 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина
ES2208942T3 (es) 1996-07-05 2004-06-16 Philip E. Branton Proteinas e4 de adenovirus para inducir la muerte celular.
JP2001508054A (ja) 1996-12-30 2001-06-19 イノジェネティックス・ナムローゼ・フェンノートシャップ ＨＢｓＡｇ由来アネキシンＶ結合ポリペプチドおよびその使用
CN1168495C (zh) 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
US6242570B1 (en) * 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
WO1999002992A1 (en) 1997-07-11 1999-01-21 The Mount Sinai School Of Medicine Of The City University Of New York Assays for diagnosis of thrombophilic disease
DE19734648A1 (de) * 1997-08-11 1999-02-18 Dade Behring Marburg Gmbh Verwendung von Annexinen als Lupus Antikoagulans Kontrolle oder Standard in Gerinnungstesten
US6511829B1 (en) 1997-10-09 2003-01-28 The Regents Of The University Of California GFP-annexin fusion proteins
AU756303B2 (en) 1997-11-06 2003-01-09 Innogenetics N.V. Host derived proteins binding HCV: medical, diagnostic and purification use
EP1064378A2 (en) 1998-03-27 2001-01-03 The Board Of Trustees Of The Leland Stanford Junior University Hypoxia-inducible human genes, proteins, and uses thereof
US20040002056A1 (en) * 1998-05-12 2004-01-01 Lorens James B. Methods of screening for bioactive agents using cells transformed with self-inactivating viral vectors
US6169078B1 (en) * 1998-05-12 2001-01-02 University Of Florida Materials and methods for the intracellular delivery of substances
AU750414B2 (en) * 1998-07-13 2002-07-18 Board Of Regents, The University Of Texas System Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
IL125908A (en) 1998-08-24 2005-05-17 Nst Neurosurvival Technologies Peptides and pharmaceutical compositions comprising same
WO2000010673A1 (en) 1998-08-24 2000-03-02 Nst Neurosurvival Technologies Ltd. Apparatus and method for capturing particles with surface exposure of anionic phospholipids from biological fluids
BR9913226A (pt) 1998-09-01 2001-05-22 Innogenetics Nv Benzodiazepinas e derivados de benzotiazepinas e peptìdios de hbsag ligados a anexinas, suas composições e uso
US6387366B1 (en) * 1998-12-31 2002-05-14 Alg Company Methods for reducing adverse side effects associated with cellular transplantation
US6323313B1 (en) * 1999-06-01 2001-11-27 The University Of Washington Annexin derivative with endogenous chelation sites
US20020088015A1 (en) * 1999-06-04 2002-07-04 Yang Shi Wilms' tumor wt1 binding proteins
CA2378079C (en) * 1999-07-28 2008-11-18 Interface Biotech A/S In vitro repair of bone and/or cartilage defects
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
WO2001023426A2 (en) 1999-09-30 2001-04-05 Varian Associates, Inc. Hypoxia-related human genes, proteins, and uses thereof
WO2001033228A2 (en) 1999-11-03 2001-05-10 Oncotech, Inc. Cancer diagnosis employing cell-sorting and gene-profiles
US20030113330A1 (en) * 1999-11-08 2003-06-19 Uhal Bruce D. Methods for treating pulmonary fibrosis
FR2809181B1 (fr) * 2000-05-16 2002-10-25 Biocytex Monoreactif pour le dosage des microparticules plaquettaires
US7449308B2 (en) * 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
AU2001288914A1 (en) 2000-09-08 2002-03-22 Board Of Regents, The University Of Texas System Biopanning and rapid analysis of selective interactive ligands (brasil)
US7582443B2 (en) * 2000-11-28 2009-09-01 Philip Gerard Cavanaugh Method for the detection and measurement of Hapten-conjugated biological binding entities by western and dot-blot using anti-hapten antibodies
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002067857A2 (en) * 2001-02-21 2002-09-06 Surromed, Inc. Modified annexin proteins and methods for preventing thrombosis
US20050222030A1 (en) 2001-02-21 2005-10-06 Anthony Allison Modified annexin proteins and methods for preventing thrombosis
US20030036699A1 (en) 2001-02-21 2003-02-20 Imetrx, Inc. Methods and systems which use annexin for bioprofiling body lumen
US7635676B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaccuticals, Inc. Modified annexin proteins and methods for their use in organ transplantation
US6843980B2 (en) 2001-04-03 2005-01-18 Theseus Imaging, Corp. Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2002087497A2 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
JP3806694B2 (ja) 2001-05-04 2006-08-09 バイオサイト インコーポレイテッド 急性冠状動脈症候群の診断マーカーおよびその使用方法
AU2002314881A1 (en) * 2001-06-07 2002-12-23 Rigel Pharmaceuticals, Inc. Cd43:modulators of mast cell degranulation
CN1343777A (zh) 2001-06-26 2002-04-10 上海动物生物技术研究中心 葡激酶与Annexin V融合基因的构建及表达
US20030152513A1 (en) * 2001-09-06 2003-08-14 Imetrix, Inc. Intravascular delivery of therapeutic and imaging agents to stressed and apoptotic cells using annexin V as a targeting vector
CN1277581C (zh) 2001-09-14 2006-10-04 浙江中奇生物药业股份有限公司 一种用蚕生产抗血栓药物的方法
DE10162434A1 (de) * 2001-12-18 2003-09-25 November Ag Molekulare Medizin Expressionsvektor und Verfahren zur Herstellung eines Expressionsvektors
US20030211548A1 (en) * 2002-01-29 2003-11-13 Oncolmmunin, Inc. Visualization and quantitiation of cellular cytotoxicity using cell-permeable fluorogenic protease substrates and caspase activity indicator markers
US7713981B2 (en) * 2002-02-28 2010-05-11 University Of Central Florida Method and compounds for inhibition of cell death
US20040029151A1 (en) 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20060134001A1 (en) 2002-07-12 2006-06-22 Frangioni John V Conjugated infrared fluorescent substances for detection of cell death
US7572442B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
CN1181099C (zh) 2002-07-23 2004-12-22 中国人民解放军第二军医大学 兼抗凝溶栓双重功能的血栓靶向融合蛋白mA5UKB
US20040042959A1 (en) * 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
DE10253526A1 (de) * 2002-11-16 2004-06-09 Johann Wolfgang Goethe-Universität Frankfurt am Main Endothelzellen als Diagnoseinstrument bei kardiovaskulären Erkrankungen
US20040203069A1 (en) 2003-04-10 2004-10-14 Chris Reutelingsperger Method for determining and/or isolating lipid-binding compounds
WO2005014801A1 (en) 2003-08-04 2005-02-17 University Court Of The University Of Edinburgh Improvements in cell culture productivity
IL157786A (en) * 2003-09-07 2010-11-30 Ahava Dead Sea Lab Ltd Personalized cosmetics
US20050084547A1 (en) * 2003-09-12 2005-04-21 Phytomyco Research Corporation Natural product based apoptosis inducers
WO2005028490A1 (en) 2003-09-19 2005-03-31 Theseus Imaging Corporation Halogenated deoxy-glucose labeled targeting molecules
US7634360B2 (en) * 2003-09-23 2009-12-15 Prediction Sciences, LL Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
EP1670510A1 (en) 2003-09-24 2006-06-21 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
CA2485722A1 (en) * 2003-10-22 2005-04-22 Paul Lehmann Soluble transferrin receptor
JP2007509163A (ja) 2003-10-22 2007-04-12 フレッド ハッチンソン キャンサー リサーチ センター 組織および臓器においてスタシスを誘導する方法、組成物、および装置
WO2005042002A2 (en) * 2003-10-30 2005-05-12 Entelos, Inc. Treatment of rhematoid arthritis with flip antagonists
JP2007512369A (ja) 2003-11-26 2007-05-17 エンテロス・インコーポレーテッド 低酸素誘導因子１αアンタゴニストを用いる慢性関節リウマチの処置
AU2005221195B2 (en) * 2004-03-11 2011-05-19 Alavita Pharmaceuticals, Inc. Modified annexin proteins and methods for preventing thrombosis
WO2005103720A1 (en) 2004-03-29 2005-11-03 Medstar Research Institute, Inc. Methods of diagnosing cardiovascular disease
EP1755642B1 (en) 2004-04-15 2010-01-13 Athera Biotechnologies Ab Annexin v for preventing plaque rupture
US20060057591A1 (en) 2004-09-15 2006-03-16 Canadian Blood Services Method for preventing viral infection
EP1819833B1 (en) 2004-11-19 2010-06-30 Universitätsklinikum Münster Genetic variant of the annexin a5 gene
WO2006060898A1 (en) 2004-12-06 2006-06-15 Aegera Therapeutics Inc Method for treating inflammatory disorders

Similar Documents

Publication Publication Date Title
Lee et al. Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis
Muehlhoefer et al. Fractalkine is an epithelial and endothelial cell-derived chemoattractant for intraepithelial lymphocytes in the small intestinal mucosa
Kahalefp et al. Autoimmunity and vascular involvement in systemic sclerosis (SSc)
Liszewski et al. Structure and regulatory profile of the monkeypox inhibitor of complement: comparison to homologs in vaccinia and variola and evidence for dimer formation
JP2018064568A5 (OSRAM)
Eshkar Sebban et al. The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation
McCloskey et al. Soluble CD23 monomers inhibit and oligomers stimulate IGE synthesis in human B cells
JP2020505932A5 (OSRAM)
JP2019521704A5 (OSRAM)
JP2004248677A5 (OSRAM)
Tsuchihashi et al. Molecular characterization of rat leukocyte P-selectin glycoprotein ligand-1 and effect of its blockade: protection from ischemia-reperfusion injury in liver transplantation
JP2017110019A (ja) 二機能性ポリペプチド
JP2014505463A5 (OSRAM)
JP2017511379A5 (OSRAM)
Kleppel et al. Evidence for separate networks of classical and novel basement membrane collagen. Characterization of alpha 3 (IV)-alport antigen heterodimer.
JP2013519721A5 (OSRAM)
de Moura et al. Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22
Kawamoto et al. LFA-1 and Mac-1 integrins bind to the serine/threonine-rich domain of thrombomodulin
Steinberg et al. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners
Schmeissner et al. Integrin functions play a key role in the differentiation of thymocytes in vivo
JP2008522162A5 (OSRAM)
Asehnoune et al. Protease-activated receptor-1: key player in the sepsis coagulation-inflammation crosstalk
Choi SLC4A transporters
JP2009540278A5 (OSRAM)
Okada et al. Liver resident macrophages (kupffer cells) share several functional antigens in common with endothelial cells